TWI417098B - (阿伐s,貝他r)-6-溴-阿伐-〔2-(二甲胺基)乙基〕-2-甲氧基-阿伐-1-萘-貝他-苯基-3-喹啉乙醇 - Google Patents

(阿伐s,貝他r)-6-溴-阿伐-〔2-(二甲胺基)乙基〕-2-甲氧基-阿伐-1-萘-貝他-苯基-3-喹啉乙醇 Download PDF

Info

Publication number
TWI417098B
TWI417098B TW096146000A TW96146000A TWI417098B TW I417098 B TWI417098 B TW I417098B TW 096146000 A TW096146000 A TW 096146000A TW 96146000 A TW96146000 A TW 96146000A TW I417098 B TWI417098 B TW I417098B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
peg
tablet
composition according
mixture obtained
Prior art date
Application number
TW096146000A
Other languages
English (en)
Chinese (zh)
Other versions
TW200838527A (en
Inventor
Jean Francois Alexandre Lucas Hegyi
Wim Albert Alex Aelterman
Yolande Lydia Lang
Sigrid Carl Maria Stokbroekx
Carina Leys
Remoortere Peter Jozef Maria Van
Anne Faure
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI417098(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of TW200838527A publication Critical patent/TW200838527A/zh
Application granted granted Critical
Publication of TWI417098B publication Critical patent/TWI417098B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096146000A 2006-12-05 2007-12-04 (阿伐s,貝他r)-6-溴-阿伐-〔2-(二甲胺基)乙基〕-2-甲氧基-阿伐-1-萘-貝他-苯基-3-喹啉乙醇 TWI417098B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05

Publications (2)

Publication Number Publication Date
TW200838527A TW200838527A (en) 2008-10-01
TWI417098B true TWI417098B (zh) 2013-12-01

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096146000A TWI417098B (zh) 2006-12-05 2007-12-04 (阿伐s,貝他r)-6-溴-阿伐-〔2-(二甲胺基)乙基〕-2-甲氧基-阿伐-1-萘-貝他-苯基-3-喹啉乙醇

Country Status (34)

Country Link
US (1) US8546428B2 (enExample)
EP (1) EP2086940B1 (enExample)
JP (2) JP2010511663A (enExample)
KR (1) KR101514700B1 (enExample)
CN (2) CN105012303A (enExample)
AP (1) AP2498A (enExample)
AR (1) AR064149A1 (enExample)
AU (1) AU2007328945B2 (enExample)
BR (1) BRPI0719693A2 (enExample)
CA (1) CA2668512C (enExample)
CL (1) CL2007003472A1 (enExample)
CY (1) CY1113594T1 (enExample)
DK (1) DK2086940T3 (enExample)
EA (1) EA017091B9 (enExample)
ES (1) ES2387923T3 (enExample)
HK (1) HK1214513A1 (enExample)
HR (1) HRP20120639T1 (enExample)
IL (1) IL199077A (enExample)
JO (1) JO2973B1 (enExample)
ME (1) ME01456B (enExample)
MX (1) MX2009005909A (enExample)
MY (1) MY148844A (enExample)
NO (1) NO342773B1 (enExample)
NZ (1) NZ576485A (enExample)
PE (1) PE20081350A1 (enExample)
PL (1) PL2086940T3 (enExample)
PT (1) PT2086940E (enExample)
RS (1) RS52408B (enExample)
SI (1) SI2086940T1 (enExample)
TW (1) TWI417098B (enExample)
UA (1) UA97813C2 (enExample)
UY (1) UY30762A1 (enExample)
WO (1) WO2008068231A1 (enExample)
ZA (1) ZA200903907B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
FI3250182T3 (fi) * 2015-01-27 2023-06-28 Janssen Pharmaceutica Nv Dispergoituvia koostumuksia
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
RU2018111482A (ru) * 2015-10-20 2019-11-21 Чжэцзян Хисунь Фармасьютикал Ко., Лтд. Кристаллические формы бедаквилин фумарата и способы их получения
DK3971177T3 (da) * 2016-07-20 2024-07-15 Novartis Ag Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
SI3943070T1 (sl) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv, Dolgo delujoče formulacije bedakilina
JP7654544B2 (ja) * 2018-12-13 2025-04-01 マンカインド コーポレイション ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
WO2020144197A1 (en) 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200401939A (en) * 2002-06-19 2004-02-01 Seiko Epson Corp Optical modulator, optical device and projector

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
WO1998018326A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
IL122026A0 (en) * 1996-10-30 1998-03-10 Lilly Co Eli Improvements in or relating to the prophylaxis of breast cancer
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1753427B1 (en) * 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200401939A (en) * 2002-06-19 2004-02-01 Seiko Epson Corp Optical modulator, optical device and projector

Also Published As

Publication number Publication date
EA017091B9 (ru) 2014-10-30
UA97813C2 (uk) 2012-03-26
MX2009005909A (es) 2009-06-16
JP2015028049A (ja) 2015-02-12
CA2668512C (en) 2015-03-24
AP2009004870A0 (en) 2009-06-30
NO20092535L (no) 2009-08-06
US20100028428A1 (en) 2010-02-04
TW200838527A (en) 2008-10-01
KR20090087020A (ko) 2009-08-14
WO2008068231A1 (en) 2008-06-12
HK1214513A1 (zh) 2016-07-29
JO2973B1 (en) 2016-03-15
SI2086940T1 (sl) 2012-09-28
AP2498A (en) 2012-10-19
US8546428B2 (en) 2013-10-01
HRP20120639T1 (hr) 2012-08-31
UY30762A1 (es) 2008-07-03
AR064149A1 (es) 2009-03-18
IL199077A (en) 2016-09-29
KR101514700B1 (ko) 2015-04-24
EA017091B1 (ru) 2012-09-28
EA200970532A1 (ru) 2009-10-30
EP2086940A1 (en) 2009-08-12
ES2387923T3 (es) 2012-10-04
JP5894239B2 (ja) 2016-03-23
MY148844A (en) 2013-06-14
RS52408B (sr) 2013-02-28
AU2007328945A1 (en) 2008-06-12
CA2668512A1 (en) 2008-06-12
PT2086940E (pt) 2012-08-09
ME01456B (me) 2014-04-20
CL2007003472A1 (es) 2008-08-22
NZ576485A (en) 2012-01-12
ZA200903907B (en) 2013-08-28
JP2010511663A (ja) 2010-04-15
CN105012303A (zh) 2015-11-04
DK2086940T3 (da) 2012-08-20
PL2086940T3 (pl) 2012-10-31
EP2086940B1 (en) 2012-05-16
AU2007328945B2 (en) 2014-04-03
PE20081350A1 (es) 2008-09-18
BRPI0719693A2 (pt) 2013-12-24
NO342773B1 (no) 2018-08-06
CY1113594T1 (el) 2016-06-22
CN101547904A (zh) 2009-09-30

Similar Documents

Publication Publication Date Title
TWI417098B (zh) (阿伐s,貝他r)-6-溴-阿伐-〔2-(二甲胺基)乙基〕-2-甲氧基-阿伐-1-萘-貝他-苯基-3-喹啉乙醇
AU2016212116B2 (en) Dispersible compositions
JPWO2001095912A1 (ja) 放出pH域及び/又は速度制御組成物
HK1210029A1 (en) Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile
CN101068597B (zh) 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
HK1137432A (en) Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
US20160058730A1 (en) Pharmaceutical compositions of teriflunomide
EA042247B1 (ru) Диспергируемые композиции
OA18325A (en) Dispersible compositions
HK1112862B (en) Furamate of 4-((4-(4-(2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
HK1112862A1 (en) Furamate of 4-((4-(4-(2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile